We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
We have recently upgraded our technology platform.
Due to this change if you are seeing this message for the first time please make sure you reset your password using the Forgot your password Link.
Ocular Therapeutix doses first patients with OTX-CSI in Phase 2 trial. (Credit: skeeze from Pixabay.)